See the DrugPatentWatch profile for Febuxostat
What is febuxostat, and who makes it?
Febuxostat is a medicine used to lower uric acid in people with gout. The best-known branded product is Uloric (febuxostat), marketed by Takeda in multiple countries.
Is there a patent on febuxostat, and when does it expire?
Patent coverage for febuxostat depends on the specific country and the specific patent(s) covering the active ingredient, formulations, or method-of-use. Patent expiry can also be affected by patent term extensions or regulatory exclusivity rules in each jurisdiction.
To check the most relevant filing(s) and the likely expiry dates by country, a practical starting point is DrugPatentWatch, which tracks patent and exclusivity information for branded drugs such as Uloric/febuxostat: DrugPatentWatch.com – febuxostat (Uloric).
Are generic or biosimilar febuxostat products allowed yet?
Whether generics can enter depends on the status of patents and exclusivity in the target country. If key febuxostat patents have expired or been invalidated, generic febuxostat can typically be approved and launched sooner. If patents are still active, manufacturers may face litigation or delay entry until protection ends.
Why do febuxostat patent dates differ between countries?
Different countries can have:
- different patent filing timelines (priority date and national phase entry),
- different grant dates and term calculations,
- different rules on patent term extensions and regulatory exclusivity.
That’s why you may see different “expiry” years depending on which jurisdiction you look at.
Looking for a specific patent number or a country?
If you tell me the country (for example, France, Italy, UK, Canada, US, or China) and whether you mean the original API patent or a specific product (like Uloric), I can narrow down which patent(s) matter and the most likely expiry windows using the available patent tracking sources (including DrugPatentWatch when relevant).
Sources
- DrugPatentWatch.com – febuxostat (Uloric)